Retatrutide Phase 3 Results: TRIUMPH-1, TRANSCEND-T2D-1, and the Full Picture

Eli Lilly has now released the complete Phase 3 dataset for retatrutide across two pivotal trials — TRIUMPH-1 (obesity) and TRANSCEND-T2D-1 (type 2 diabetes) — presented at the ADA 86th Scientific Sessions, with TRANSCEND-T2D-1 simultaneously published in The Lancet. The results extend well beyond weight loss.

This post covers the full dataset: weight outcomes, osteoarthritis, sleep apnea, diabetes, cardiovascular markers, and the complete safety profile.

---

What Is Retatrutide?

Retatrutide is a once-weekly injectable that activates three hormone receptors simultaneously:

• GIP receptor — enhances insulin sensitivity, reduces adipose inflammation, acts on fat tissue directly
• GLP-1 receptor — suppresses appetite, slows gastric emptying, reduces caloric intake
• Glucagon receptor — increases energy expenditure, drives hepatic fat oxidation

The glucagon component is the differentiator from tirzepatide (dual GIP/GLP-1). Glucagon receptor agonism has historically been avoided in metabolic drugs because it raises blood glucose — but paired with GLP-1 activity at the right ratio, that effect is neutralized while the thermogenic and hepatic benefits are preserved.

---

TRIUMPH-1: Weight Outcomes

Trial design: Adults with obesity (BMI ≥30) or overweight (BMI ≥27) with ≥1 weight-related comorbidity, without diabetes. Avg. baseline: 112.7 kg (248.5 lbs), BMI 40.0. Duration: 80 weeks.

Dose	Avg. weight loss	Avg. lbs lost
4 mg	-19.0%	-47.2 lbs
9 mg	-25.9%	-64.4 lbs
12 mg	-28.3%	-70.3 lbs
Placebo	-2.2%	-5.5 lbs

All three doses met primary and key secondary endpoints.

Responder rates at 12 mg:

• ≥25% body weight reduction: 62.5%
• ≥30% body weight reduction: 45.3% — the threshold historically associated with bariatric surgery
• ≥35% body weight reduction: 27.2%
• BMI fell below 30: 65.3% of participants
• BMI fell below 25 (healthy range): 33.3% of participants

104-week extension (BMI ≥35 cohort): Participants continuing on retatrutide 12 mg lost an average of 30.3% (-85.0 lbs). The weight loss curve had not plateaued at two years.

---

TRIUMPH-1: Knee Osteoarthritis

Nested within TRIUMPH-1 was a basket trial for participants with knee osteoarthritis. This is the first Phase 3 obesity trial to formally measure OA pain as a primary endpoint.

WOMAC pain subscale score (baseline: 6.0 out of 10):

• Retatrutide 12 mg: -4.3 points (-73.1%)
• Retatrutide 9 mg: significant reduction
• Placebo: modest improvement (consistent with weight loss alone)

A 73% reduction in knee pain from a single pharmacological intervention — one that is also driving 28% weight loss — is a clinically significant finding. It suggests the glucagon and GLP-1 components are contributing anti-inflammatory effects beyond what weight reduction alone would produce.

---

TRIUMPH-1: Obstructive Sleep Apnea

The second basket trial nested in TRIUMPH-1 targeted moderate-to-severe obstructive sleep apnea (OSA).

Apnea-hypopnea index (AHI) (baseline: 58.6 events/hour):

• Retatrutide 12 mg: -36.1 events/hour (-60.6%)

A reduction from 58.6 to ~22.5 events/hour moves most participants from severe OSA to mild or moderate. This is a meaningful functional improvement — not just a biomarker shift.

For context: tirzepatide’s SURMOUNT-OSA trial showed ~55% AHI reduction. Retatrutide is in the same range, which suggests the effect is largely mediated by weight loss rather than a retatrutide-specific mechanism.

---

TRANSCEND-T2D-1: Type 2 Diabetes

TRANSCEND-T2D-1 enrolled adults with type 2 diabetes and obesity. Duration: 40 weeks. Published in The Lancet.

Primary endpoint: A1C reduction from baseline of 7.9%

Dose	A1C reduction	Weight loss
4 mg	significant	significant
9 mg	significant	significant
12 mg	-2.0%	-16.8% (-36.6 lbs)
Placebo	minimal	minimal

A1C responder rates on retatrutide (best dose):

• A1C <7.0% (ADA general target): 90% of participants
• A1C ≤6.5% (more stringent target): 85% of participants
• A1C <5.7% (normoglycemia threshold): 46% of participants

Nearly half of participants with type 2 diabetes achieved normal blood sugar levels. That is not a common outcome for any drug class. Weight loss at 40 weeks was 16.8% and not yet plateauing — suggesting continued weight reduction with longer treatment.

---

Cardiovascular Risk Factors

TRIUMPH-1 (80 weeks, 12 mg):

• Triglycerides: -41.0%
• Non-HDL cholesterol: -24.2%
• Systolic blood pressure: -12.3 mmHg
• Waist circumference: -24.1 cm (-9.5 in)

TRANSCEND-T2D-1 (40 weeks, 12 mg):

• Triglycerides: -39.6%
• Non-HDL cholesterol: -19.8%
• Systolic blood pressure: -6.4 mmHg
• Waist circumference: -12.4 cm (-4.9 in)

These are not modest improvements. A 41% reduction in triglycerides alongside 28% body weight loss and 73% OA pain reduction represents a compound that is simultaneously addressing multiple disease processes — not just weight.

---

Safety Profile

Adverse events were consistent with the incretin drug class. The notable addition versus prior GLP-1/GIP drugs is dysesthesia (tingling or abnormal skin sensation) — observed in 12.3–12.5% of participants at higher doses (vs. 0.9% placebo). Most cases were mild to moderate and resolved during treatment.

TRIUMPH-1 most common AEs (12 mg vs. placebo):

• Nausea: 42.4% vs. 14.8%
• Diarrhea: 32.0% vs. 13.5%
• Constipation: 26.1% vs. 10.9%
• Vomiting: 25.3% vs. 4.8%
• Dysesthesia: 12.5% vs. 0.9%
• UTI: 8.4% vs. 5.3%

Discontinuation due to adverse events:

• 4 mg: 4.1% (vs. 4.9% placebo)
• 9 mg: 6.9%
• 12 mg: 11.3%

The 11.3% discontinuation rate at 12 mg is higher than tirzepatide’s ~7% in SURMOUNT-1 — a real tolerability signal that will factor into clinical adoption and dosing strategy. The 4 mg arm’s 4.1% discontinuation rate (below placebo) is notable and supports the case for a lower-dose access pathway.

---

How It Compares

Compound	Peak Phase 3 weight loss	Mechanism
Semaglutide (Wegovy)	~15–17%	GLP-1 agonist
Tirzepatide (Zepbound)	~20–22.5%	GIP + GLP-1
Orforglipron (Foundayo)	~15%	Oral GLP-1
Retatrutide	~28–30%	GIP + GLP-1 + Glucagon

The glucagon receptor component appears to be adding genuine metabolic effect — the Phase 2 Nature Medicine data showed up to 82% reduction in liver fat, and the Phase 3 CV numbers (41% triglyceride reduction) are stronger than what tirzepatide produced at similar timepoints.

---

Regulatory Status

Retatrutide is not approved. It is investigational.

TRIUMPH-1 and TRANSCEND-T2D-1 are pivotal Phase 3 trials. Lilly has not announced an NDA submission date. Cardiovascular outcomes data is still pending — that trial is ongoing and will likely be required for full label approval.

Earliest plausible FDA approval: 2027, potentially accelerated with Priority Review designation given the unmet need and magnitude of effect.

Retatrutide is not legally available in the U.S. outside of clinical trials. Any product labeled “retatrutide” from compounding pharmacies or research suppliers is not this compound.

---

What to Watch

• TRIUMPH cardiovascular outcomes trial — the missing piece for a broad cardiovascular label
• NDA submission announcement — expected once CV outcomes data matures
• Dysesthesia mechanism — the skin tingling signal is unique to retatrutide among incretins; the glucagon component is the likely driver and warrants monitoring in a larger population
• Competitive pressure — Novo Nordisk’s CagriSema and amycretin are in Phase 3; the next-generation obesity drug market is racing

---

Bottom Line

The full retatrutide Phase 3 dataset is now the most comprehensive obesity drug data package ever assembled. Beyond 28% weight loss:

• 73% reduction in knee osteoarthritis pain
• 61% reduction in sleep apnea severity
• 46% of T2D patients achieving normoglycemia
• 41% reduction in triglycerides

The compound addresses obesity and four of its most common downstream complications simultaneously. The discontinuation rate at the highest dose is a real tolerability consideration. The 4 mg dose — with 19% weight loss and better tolerability — may be the clinically practical entry point for most patients.

Retatrutide is not available. If approved in 2027, it enters the market as the most effective pharmacological obesity treatment in history by a significant margin.

---

Sources: Lilly TRIUMPH-1 and TRANSCEND-T2D-1 press releases (May–June 2026); TRANSCEND-T2D-1 published in The Lancet; Jastreboff et al., Nature Medicine (Phase 2); ADA 86th Scientific Sessions. This article is for informational purposes only and does not constitute medical advice.